Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RGNX
Strong SellSinkerREGENXBIO Inc. · Healthcare · United States · $638M · Avg Vol: $11M/d
COMPANY DESCRIPTION
REGENXBIO Inc. is a leading clinical-stage biotechnology company focused on the development of gene therapies using its proprietary NAV® AAV gene delivery platform. The company's pipeline targets severe genetic diseases across ophthalmology, neurodegenerative diseases, and other therapeutic areas, with multiple programs in clinical development. REGENXBIO maintains a strong competitive moat through its extensive patent estate and broad licensing strategy for its advanced gene delivery technology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.7M | 90.2M | 83.3M | 170.4M | 14.8% | 174.5M | 167.8M | 217.0M | 12.8% |
| EPS | -6.50 | -6.02 | -4.59 | -3.76 | — | -3.78 | -3.52 | -3.00 | — |
| Shares | 43.3M | 44.0M | 49.5M | 50.9M | +17.5% | 66.0M | — | — | — |
| Debt | 94.8M | 89.3M | 82.0M | 73.5M | -8.1% | 250.5M | — | — | — |
| Equity | 516.2M | 311.7M | 259.7M | 102.7M | -41.6% | — | — | — | — |
| Op CF | -207.5M | -218.4M | -173.1M | -124.0M | — | -246.7M | — | — | — |
| Inv CF | -11.9M | 190.9M | 103.4M | -15.9M | — | — | — | — | — |
| Fin CF | -28.8M | -35.0M | 92.7M | 116.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RGNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc.(you) | $638M | 8 | Strong Sell |
| 950260.KQ | Ingenia Therapeutics Inc. | $649M | 7 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 8 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 7 | Strong Sell |
| SPRY | ARS Pharmaceuticals, Inc. | $586M | 6 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 10 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 7 | Strong Sell |
| CTMX | CytomX Therapeutics, Inc. | $699M | 12 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 8 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%